PharmaLex Group Completes Merger with BioStat Solutions

Publication
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter 10-07-2020
Volume 15
Issue 10

The merged company can offer enhanced statistical and data analytics services.

PharmaLex Group, a pharma, biotech and medical device industries provider, completed its merger with BioStat Solutions (BSSI), a data analytics company. The merged company will enhance service offerings in data analytics. BSSI strengths lay in analytical solutions that can resolve data complexities and expertise in high-dimensional data, including real-world evidence and -omics data, according to a Sept. 29, 2020 press release.

Under the terms of the merger, Lin Li, the senior director of Scientific Operations at BSSI will take over management of BSSI, Ron Bromley will step down from his position as CEO of BSSI, and Ena Bromley will continue to hold her position as non-executive director and principal consultant at BSSI.

“PharmaLex is a leading service provider in the pharma, biotech, and medical device industries,” said Li in the press release. “It is an exciting challenge to support them in developing their statistical solutions services and I look forward to leading the US team.”

“BSSI has had a focus on translational medicine and bioinformatics,” added Dr. Thomas Dobmeyer, CEO, PharmaLex, in the press release. “Their service portfolio complements nicely with our existing statistical solutions which focuses more on Bayesian statistics and will allow us to further enhance the services we are able to offer our clients—within the growing biomarker and bioinformatics market, which are both expected to grow with >13% per annum.”

Source: PharmaLex​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Articles in this issue
Restructuring Method Transfer Throughout Global Sites
Restructuring Method Transfer Throughout Global Sites
Darren Baker/Stock.Adobe.com - scientist observing test tube
When Assessing Protein Aggregation Grows Increasingly Challenging
Almac Sciences Adds Biologics Testing to its Analytical Solutions Suite
PharmaLex Group Completes Merger with BioStat Solutions
Natoli Installs Tablet Press at its New Research and Training Facility
Thermo Fisher to Invest More than $140 Million into its Lab Plastics Consumables for COVID-19 Testing
Sai Life Sciences’ Screening Capabilities Enhanced with Expanded Cellular Analysis Platforms
StarBright Violet 515 Dye from Bio-Rad Enhances Flow Cytometry
Paradigm4’s Single Cell App Allows for Analysis of Large-Scale Datasets
CytoSMART Technologies’ New Automated Live-Cell Imaging System Keeps Lab Teams Coordinated
Promega’s New Capillary Electrophoresis Instrument Enhances Benchtop Analysis
Aigenpulse’s Data Analysis Suite Automates Flow Cytometry
Recent Videos
Behind the Headlines episode 6
Drug Digest: Is Our Understanding of Stability Changing
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Circio and Certest to Collaborate on LNP Formulations

Feliza Mirasol
November 21st 2024
Article

The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.

Drug Solutions Podcast: Dosage Forms: Roundtable on Oral Solid Dosage Trends

Drug Solutions Podcast: Dosage Forms: Roundtable on Oral Solid Dosage Trends

Patrick Lavery
October 30th 2024
Podcast

In this podcast episode, we discuss trends in dosage forms, specifically oral solid dosage, as viewed by five industry experts who recently exhibited at CPHI Milan.

Site Logo

Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies

Eurofins
November 21st 2024
Article

Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.

Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?

Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?

PDA
October 10th 2024
Podcast

Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.

Site Logo

Ensuring Quality from the Start: Raw Materials Testing Support

Eurofins
November 21st 2024
Article

Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.

Site Logo

Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing

Eurofins
November 21st 2024
Article

Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.